Inclusion Criteria

Inclusion criteria:

1. Adults ≥ 18 years old

2. Diagnosis of symptomatic multiple myeloma (per IMWG see Kyle et al 2003)

3. Subjects must have received at least two prior lines of therapy and be refractory to
the most recent line of therapy

4. Subjects must have previously been treated with : bortezomib or lenalidomide

5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2

6. Patients must have adequate laboratory values

7. Baseline left ventricular ejection fraction LVEF ≥ the lower limit of the
institutional normal

Exclusion criteria:

1. Prior therapy with a histone deacetylase inhibitor (HDAC)

2. Impaired cardiac function or clinically significant cardiac diseases

3. Impairment of gastrointestinal function (GI) function or GI disease that may
significantly alter the absorption of LBH589

4. Patients with unresolved diarrhea > Common Terminology Criteria for Adverse Events
(CTCAE) grade 1

5. Concomitant use of certain medications

6. Patients who have received chemotherapy, radiation therapy or any investigational
drugs, bortezomib or other immunomodulatory therapy or immunotherapy ≤ 3 weeks prior
to starting study drug or who have not recovered from side effects of such therapy

7. Patients who have received steroids ≤ 2 weeks prior to starting study treatment or
who have not recovered from side effects of such therapy.

8. Patients who have received high-dose corticosteroids as the only component of their
most recent line of therapy

9. Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or
who have not recovered from side effects of such therapy

10. Women who are pregnant or breast feeding or women of childbearing potential not using
an effective method of birth control.

Other protocol-defined inclusion/exclusion criteria may apply